These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 7913116)

  • 41. Maturation of adult peripheral blood CD38(+)CD4(+) T cells demonstrated by cytokine production in response to a superantigen, TSST-1.
    Imanishi K; Kato H; Fujii H; Uchiyama T
    Cell Immunol; 2003 Apr; 222(2):89-96. PubMed ID: 12826078
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [CD38/ADP-ribosyl cyclase, a marker of endothelial dysfunction in bronchial asthma].
    Sobko EA; Kraposhina AIu; Demko IV; Salmina AB
    Klin Med (Mosk); 2013; 91(2):34-8. PubMed ID: 23718062
    [TBL] [Abstract][Full Text] [Related]  

  • 43. NKRP1A molecule is involved in transendothelial migration of CD4+ human T lymphocytes.
    Poggi A; Costa P; Zocchi MR; Moretta L
    Immunol Lett; 1997 Jun; 57(1-3):121-3. PubMed ID: 9232437
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Lymphocyte adhesion to endothelium.
    Dianzani U; Malavasi F
    Crit Rev Immunol; 1995; 15(2):167-200. PubMed ID: 8573287
    [TBL] [Abstract][Full Text] [Related]  

  • 45. CD38: an ecto-enzyme with functional diversity in T cells.
    Ghosh A; Khanam A; Ray K; Mathur P; Subramanian A; Poonia B; Kottilil S
    Front Immunol; 2023; 14():1146791. PubMed ID: 37180151
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Functional SARS-CoV-2 cross-reactive CD4
    Humbert M; Olofsson A; Wullimann D; Niessl J; Hodcroft EB; Cai C; Gao Y; Sohlberg E; Dyrdak R; Mikaeloff F; Neogi U; Albert J; Malmberg KJ; Lund-Johansen F; Aleman S; Björkhem-Bergman L; Jenmalm MC; Ljunggren HG; Buggert M; Karlsson AC
    Proc Natl Acad Sci U S A; 2023 Mar; 120(12):e2220320120. PubMed ID: 36917669
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Innovative Anti-CD38 and Anti-BCMA Targeted Therapies in Multiple Myeloma: Mechanisms of Action and Resistance.
    De Novellis D; Fontana R; Giudice V; Serio B; Selleri C
    Int J Mol Sci; 2022 Dec; 24(1):. PubMed ID: 36614086
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Leukocyte Membrane Enzymes Play the Cell Adhesion Game.
    López-Cortés GI; Díaz-Alvarez L; Ortega E
    Front Immunol; 2021; 12():742292. PubMed ID: 34887854
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Immunological age prediction in HIV-infected, ART-treated individuals.
    de Armas LR; Pallikkuth S; Pan L; Rinaldi S; Pahwa R; Pahwa S
    Aging (Albany NY); 2021 Oct; 13(19):22772-22791. PubMed ID: 34635604
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Correlation of CD38 expression with the progression of hemorrhagic fever with renal syndrome.
    Zhao HD; Li YP; Zhao WW; Li P; Liu HL
    Arch Virol; 2021 Sep; 166(9):2399-2406. PubMed ID: 34114140
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Mass Cytometry Identifies Expansion of T-bet
    Couloume L; Ferrant J; Le Gallou S; Mandon M; Jean R; Bescher N; Zephir H; Edan G; Thouvenot E; Ruet A; Debouverie M; Tarte K; Amé P; Roussel M; Michel L
    Front Immunol; 2021; 12():653577. PubMed ID: 34017332
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The role of CD38 in HIV infection.
    Lu L; Wang J; Yang Q; Xie X; Huang Y
    AIDS Res Ther; 2021 Apr; 18(1):11. PubMed ID: 33820568
    [TBL] [Abstract][Full Text] [Related]  

  • 53. CD38 in the age of COVID-19: a medical perspective.
    Horenstein AL; Faini AC; Malavasi F
    Physiol Rev; 2021 Oct; 101(4):1457-1486. PubMed ID: 33787351
    [TBL] [Abstract][Full Text] [Related]  

  • 54. IFN-γ and CD38 in Hyperprogressive Cancer Development.
    Angelicola S; Ruzzi F; Landuzzi L; Scalambra L; Gelsomino F; Ardizzoni A; Nanni P; Lollini PL; Palladini A
    Cancers (Basel); 2021 Jan; 13(2):. PubMed ID: 33467713
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Immunological imprint of COVID-19 on human peripheral blood leukocyte populations.
    Kratzer B; Trapin D; Ettel P; Körmöczi U; Rottal A; Tuppy F; Feichter M; Gattinger P; Borochova K; Dorofeeva Y; Tulaeva I; Weber M; Grabmeier-Pfistershammer K; Tauber PA; Gerdov M; Mühl B; Perkmann T; Fae I; Wenda S; Führer H; Henning R; Valenta R; Pickl WF
    Allergy; 2021 Mar; 76(3):751-765. PubMed ID: 33128792
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Bispecific Antibodies for Multiple Myeloma: A Review of Targets, Drugs, Clinical Trials, and Future Directions.
    Caraccio C; Krishna S; Phillips DJ; Schürch CM
    Front Immunol; 2020; 11():501. PubMed ID: 32391000
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Roles of CD38 in the Immune Response to Infection.
    Glaría E; Valledor AF
    Cells; 2020 Jan; 9(1):. PubMed ID: 31963337
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Current advances in chimeric antigen receptor T-cell therapy for refractory/relapsed multiple myeloma.
    Huang H; Wu HW; Hu YX
    J Zhejiang Univ Sci B; 2020 Jan.; 21(1):29-41. PubMed ID: 31898440
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The Good, the Bad and the Unknown of CD38 in the Metabolic Microenvironment and Immune Cell Functionality of Solid Tumors.
    Konen JM; Fradette JJ; Gibbons DL
    Cells; 2019 Dec; 9(1):. PubMed ID: 31878283
    [TBL] [Abstract][Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.